Ranbaxy is India's top pharmaceutical company, manufacturing and marketing branded generic pharmaceuticals products and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on US and European markets has helped it build deep product pipelines... More in both the markets. The company has a global footprint in 43 countries, manufacturing facilities in 8 countries and serves customers in over 125 countries. In 2008, Ranbaxy's promoters sold their entire stake to Daiichi Sankyo of Japan, which now holds 62% stake in Ranbaxy.
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More 48% in the US-based Caraco Pharma. Currently, the stake in Caraco stands at 76%. Exports contribute around 56% to revenues. With the help of Caraco, Sun Pharma has been able to grow its US business, which brings in synergies by way of backward integration in both manufacturing and R&D.
Capital First announced its results for the third quarter and first nine months of the financial year 2014-15 (9mFY15). The institution grew its income from operations by 34.4% YoY and the profits by 240% YoY during 9mFY15